Moderate renal impairment does not preclude the accuracy of 24‐hour urine normetanephrine measurements for suspected pheochromoctyoma

2020 ◽  
Vol 92 (6) ◽  
pp. 518-524
Author(s):  
Gregory A. Kline ◽  
Jessica Boyd ◽  
Alex A. Leung ◽  
Andrew Tang ◽  
Hossein M. Sadrzadeh
Keyword(s):  
Renal Impairment ◽  
Moderate Renal Impairment

1004-P: Oral Semaglutide vs. Placebo in Patients with Type 2 Diabetes and Moderate Renal Impairment: PIONEER 5

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 1004-P ◽  
Author(s):  
OFRI MOSENZON ◽  
SIGNE ROSENLUND ◽  
JAN W. ERIKSSON ◽  
SIMON R. HELLER ◽  
RICHARD E. PRATLEY ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Renal Impairment ◽  
Moderate Renal Impairment

scholarly journals Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction.

1996 ◽  
Vol 40 (6) ◽  
pp. 1514-1519 ◽  
Author(s):  
A E Heald ◽  
P H Hsyu ◽  
G J Yuen ◽  
P Robinson ◽  
P Mydlow ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Renal Function ◽  
Renal Impairment ◽  
Normal Renal Function ◽  
Severe Renal Impairment ◽  
Moderate Renal Impairment ◽  
Pharmacokinetic Parameters ◽  
Geometric Means ◽  
Immunodeficiency Virus

The purpose of this study was to determine the safety and pharmacokinetics of lamivudine (3TC), a nucleoside analog that has shown potent in vitro and recent in vivo activity against human immunodeficiency virus. Sixteen human immunodeficiency virus-infected patients, six with normal renal function (creatinine clearance [CLCR], > or = 60 ml/min), four with moderate renal impairment (CLCR, 10 to 40 ml/min), and six with severe renal impairment (CLCR, < 10 ml/min), were enrolled in the study. After an overnight fast, patients were administered 300 mg of 3TC orally. Blood was obtained before 3TC administration and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 32, 40, and 48 h afterward. Timed urine collections were performed for patients able to produce urine. Serum and urine were assayed for 3TC by reverse-phase high-performance liquid chromatography with UV detection. Pharmacokinetic parameters were calculated by using standard noncompartmental techniques. The peak concentration of 3TC increased with decreasing renal function; geometric means were 2,524, 3,538, and 5,684 ng/ml for patients with normal renal function, moderate renal impairment, and severe renal impairment, respectively. The terminal half-life also increased with decreasing renal function; geometric means were 11.5, 14.1, and 20.7 h for patients with normal renal function, moderate renal impairment, and severe renal impairment, respectively. Both oral and renal clearances were linearly correlated with CLCR. A 300-mg dose of 3TC was well tolerated by all three patient groups. The pharmacokinetics of 3TC is profoundly affected by impaired renal function. Dosage adjustment, by either dose reduction or lengthening of the dosing interval, is warranted.

Efficacy and safety of ledipasvir/sofosbuvir for genotype 1b chronic hepatitis C patients with moderate renal impairment

2018 ◽  
Vol 12 (2) ◽  
pp. 133-142 ◽  
Author(s):  
Tomomi Okubo ◽  
Masanori Atsukawa ◽  
Akihito Tsubota ◽  
Hidenori Toyoda ◽  
Noritomo Shimada ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Renal Impairment ◽  
Chronic Hepatitis C ◽  
Moderate Renal Impairment ◽  
Efficacy And Safety ◽  
Genotype 1B ◽  
Chronic Hepatitis C Patients

scholarly journals Saxagliptin Efficacy and Safety in Patients With Type 2 Diabetes and Moderate Renal Impairment

2016 ◽  
Vol 7 (3) ◽  
pp. 527-535 ◽  
Author(s):  
Shira Perl ◽  
William Cook ◽  
Cheryl Wei ◽  
Nayyar Iqbal ◽  
Boaz Hirshberg
Keyword(s):  
Type 2 Diabetes ◽  
Renal Impairment ◽  
Moderate Renal Impairment ◽  
Efficacy And Safety

scholarly journals The effect of mild and moderate renal impairment on the pharmacokinetics of pridopidine, a new drug for Huntington's disease

2015 ◽  
Vol 81 (2) ◽  
pp. 246-255 ◽  
Author(s):  
L. Rabinovich‐Guilatt ◽  
K. E. Siegler ◽  
A. Schultz ◽  
A. Halabi ◽  
A. Rembratt ◽  
...  
Keyword(s):  
Renal Impairment ◽  
Huntington's Disease ◽  
Huntington’S Disease ◽  
Moderate Renal Impairment ◽  
New Drug
Sign in / Sign up

Export Citation Format

Share Document